中光防雷(300414.SZ):擬參投共青城優創超越創業投資合夥企業
格隆匯7月4日丨中光防雷(300414.SZ)公佈,2025年7月初,四川中光防雷科技股份有限公司與深圳藍海優創基金管理有限公司(簡稱“藍海基金”)等合作方簽署了《共青城優創超越創業投資合夥企業(有限合夥)合夥協議》。公司擬作為有限合夥人之一參與投資共青城優創超越創業投資合夥企業(有限合夥)(簡稱“基金”或“優創超越”)。優創超越將在中國證券投資基金業協會備案後開展投資活動,直接或間接投資成都超德創科技有限公司,基金本次總認繳出資額為人民幣2102萬元,其中公司擬以自有資金認繳出資人民幣500萬元,持有基金23.7869%的份額。合夥企業專項投資於成都超德創科技有限公司的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.